Pulmonary Tuberculosis Therapeutics
1. Aemcolo patent expiration
Treatment: Treatment of travelers' diarrhea caused by non-invasive strains of escherichia coli in adults
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8741948 | COSMO TECHNOLOGIES | Oral antimicrobial pharmaceutical compositions |
May, 2025
(8 months ago) | |
| US8529945 | COSMO TECHNOLOGIES | Oral antimicrobial pharmaceutical compositions |
May, 2025
(8 months ago) | |
| US8263120 | COSMO TECHNOLOGIES | Oral antimicrobial pharmaceutical compositions |
May, 2025
(8 months ago) | |
| US8486446 | COSMO TECHNOLOGIES | Oral antimicrobial pharmaceutical compositions |
May, 2025
(8 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 16, 2023 |
| Generating Antibiotic Incentives Now(GAIN) | Nov 16, 2028 |
Drugs and Companies using RIFAMYCIN SODIUM ingredient
NCE-1 date: 17 November, 2027
Market Authorisation Date: 16 November, 2018
Dosage: TABLET, DELAYED RELEASE
More Information on Dosage
AEMCOLO family patents
